1741-7015-7-26 1741-7015 Review <p>Varicella vaccination in Europe – taking the practical approach</p> Bonanni Paolo paolo.bonanni@unifi.it Breuer Judith j.breuer@qmul.ac.uk Gershon Anne aag1@columbia.edu Gershon Michael mdg4@columbia.edu Hryniewicz Waleria waleria@cls.edu.pl Papaevangelou Vana vpapaev@med.uoa.gr Rentier Bernard brentier@ulg.ac.be Rümke Hans rumke@vaxinostics.com Sadzot-Delvaux Catherine csadzot@ulg.ac.be Senterre Jacques senterre.jacques@belgacom.net Weil-Olivier Catherine catweiloli@hotmail.com Wutzler Peter peter.wutzler@med.uni-jena.de

Department of Public Health, University of Florence, Florence, Italy

Skin Virus Laboratory, Centre for Cutaneous Research, St Bartholomew's and The Royal London School of Medicine and Dentistry, Queen Mary College, London, UK

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, USA

Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, USA

National Medicines Institute, Chelmska Street, 00-725 Warsaw, Poland

Second Department of Pediatrics, University of Athens Medical School, "P & A Kyriakou" Children's Hospital, Athens, Greece

Unit of Fundamental Virology and Immunology, GIGA-Research, B34 University of Liége, 4000 Liège, Belgium

Vaxinostics, University Vaccine Center Rotterdam Nijmegen, Rotterdam, the Netherlands

Department of Pediatrics, University of Liège, Liège, Belgium

University Paris VII, Paris 75005, France

Institute of Virology and Antiviral Therapy, Friedrich-Schiller University, Jena, Germany

BMC Medicine 1741-7015 2009 7 1 26 http://www.biomedcentral.com/1741-7015/7/26 19476611 10.1186/1741-7015-7-26
12 2 2009 28 5 2009 28 5 2009 2009 Bonanni et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Varicella is a common viral disease affecting almost the entire birth cohort. Although usually self-limiting, some cases of varicella can be serious, with 2 to 6% of cases attending a general practice resulting in complications. The hospitalisation rate for varicella in Europe ranges from 1.3 to 4.5 per 100,000 population/year and up to 10.1% of hospitalised patients report permanent or possible permanent sequelae (for example, scarring or ataxia). However, in many countries the epidemiology of varicella remains largely unknown or incomplete.

In countries where routine childhood vaccination against varicella has been implemented, it has had a positive effect on disease prevention and control. Furthermore, mathematical models indicate that this intervention strategy may provide economic benefits for the individual and society. Despite this evidence and recommendations for varicella vaccination by official bodies such as the World Health Organization, and scientific experts in the field, the majority of European countries (with the exception of Germany and Greece) have delayed decisions on implementation of routine childhood varicella vaccination, choosing instead to vaccinate high-risk groups or not to vaccinate at all.

In this paper, members of the Working Against Varicella in Europe group consider the practicalities of introducing routine childhood varicella vaccination in Europe, discussing the benefits and challenges of different vaccination options (vaccination vs. no vaccination, routine vaccination of infants vs. vaccination of susceptible adolescents or adults, two doses vs. one dose of varicella vaccine, monovalent varicella vaccines vs. tetravalent measles, mumps, rubella and varicella vaccines, as well as the optimal interval between two doses of measles, mumps, rubella and varicella vaccines).

Assessment of the epidemiology of varicella in Europe and evidence for the effectiveness of varicella vaccination provides support for routine childhood programmes in Europe. Although European countries are faced with challenges or uncertainties that may have delayed implementation of a childhood vaccination programme, many of these concerns remain hypothetical and with new opportunities offered by combined measles, mumps, rubella and varicella vaccines, reassessment may be timely.

Background

Varicella is a highly contagious disease caused by the varicella zoster virus (VZV), a member of the alpha herpesvirus family. Varicella (or chickenpox) is characterised by a vesicular rash, usually accompanied by fever and malaise 1.

In 1998, the World Health Organization (WHO) recommended that routine childhood varicella vaccination be considered in countries where the disease is a relatively important public health and socioeconomic problem, where the vaccine is affordable, and where high (85 to 90%) and sustained vaccine coverage can be achieved 2. More than 10 years later, the varicella vaccine is used in childhood immunisation programmes in Australia 3, Canada 4, Germany 5, Greece 6, Qatar 7, Republic of Korea 8, Saudi Arabia 7, Taiwan 9, United States of America (USA) 10, Uruguay 11 and parts of Italy (Sicily) 8 and Spain (Autonomous Community of Madrid) 12.

However, recommendations for varicella vaccination in Europe vary, with the majority of countries not following the WHO recommendations for universal routine vaccination (URV), instead recommending vaccination of susceptible adolescents or high-risk groups. Furthermore, despite the proven health benefits of varicella vaccination 1113141516, most European countries have delayed the introduction of the vaccine into their immunisation schedules.

This paper seeks to explore the basis of the WHO recommendation in relation to the clinical epidemiology of varicella in Europe, and to understand the reasons for the recommendations not being widely adopted in this region. The practicalities of introducing varicella vaccination into national childhood immunisation calendars in Europe are also evaluated, including discussion on the benefits and challenges of different schedules for monovalent varicella vaccines (Varilrix™, GlaxoSmithKline Biologicals, Rixensart, Belgium and Varivax™ Sanofi Pasteur MSD, Lyon, France) and for the new combination measles, mumps, rubella, varicella (MMRV) vaccines (Priorix-Tetra™, GlaxoSmithKline Biologicals, Rixensart, Belgium and ProQuad™, Sanofi Pasteur MSD, Lyon, France).

Why vaccinate against varicella in Europe?

The clinical epidemiology of varicella in Europe is summarised in Table S1 (Additional file 1) (mortality) 171819202122232425262728293031 and Additional file 2 (incidence, hospitalisations and complications) 1217181920212223242526272930323334353637383940414243. It is noteworthy that differences in study methodology mean that epidemiological information cannot be easily compared across studies. Furthermore, the majority of studies were conducted in hospitals, with few data available from non-hospitalised patients. In many European countries, such as Belgium and the United Kingdom (UK), the true clinical impact of varicella remains to be determined because it is not a notifiable disease. In other countries, epidemiological data are available, but they may not accurately reflect the true burden of varicella given under-reporting to statutory notification systems 38. For example, in Italy, the age-standardised incidence of varicella in children 0 to14 years of age collected from a paediatric sentinel network of primary care physicians was 3.8-fold higher than that from statutory notifications (P < 0.0001) 38.

<p>Additional file 1</p>

Tables S1–S3. Table S1 – Summary of varicella-related mortality data from European countries. Table S2 – Seroprevalence of varicella among children in Europe. Table S3 – Recommendations for varicella and measles-mumps-rubella (MMR) vaccination in European countries.

Click here for file

<p>Additional file 2</p>

Supplementary appendix. Summary of varicella epidemiology in European countries.

Click here for file

Varicella incidence and seroprevalence

Population surveys described in Additional file 2 reveal that varicella is a common disease in European countries affecting nearly the entire birth cohort. For example, in Germany there was an annual incidence of approximately 760,000 new varicella cases in a birth cohort of around 800,000 prior to widespread vaccination in 1999 35.

In Europe, the sero-epidemiology of VZV characterises varicella as a disease of childhood, with rapid acquisition of antibodies to VZV during early life 24444546474849505152. By adolescence, the majority of individuals are seropositive for VZV antibodies 4445. However, there are differences across the European region 44; seroprevalence appears to be slightly lower among children in southern European countries 5152 than in northern or central European countries (Table S2 in Additional file 1) 4853, which may be explained by different climates (Mediterranean vs. continental) 54. Some European countries, such as the UK and Belgium, report a higher seroprevalence among children younger than 4 years of age than other parts of Europe, attributed to the high-level use of day-care nurseries and pre-school facilities 485556.

Hospitalisations and complications from varicella

While usually self-limiting, a case of varicella can develop potentially serious complications (estimated in approximately 2 to 6% of cases attending a general practice; Additional file 2) 355758. Common complications in individuals hospitalised with varicella include superinfection of the skin, respiratory complications and neurological manifestations (for example, cerebellitis and encephalitis) 2130323641. Although seldom reported, long-term (including permanent or possible permanent) sequelae, which include severe scarring, ataxia/coordination disorder, epilepsy and cerebral nerve paralysis, occur in 0.4 to 10.1% of patients hospitalised for varicella (Additional file 2) 202136.

In the European studies identified, the incidence of hospitalisation for varicella ranged from 1.3 to 4.5 per 100,000 population/year 2427282943 and 12.9 to 28.0 per 100,000 children ≤ 16 years/year 1720213242, with an average duration of hospital stay ranging from 3 to 8 days (Additional file 2) 1920222427303334354243. Most complications and hospitalisations for varicella occurred in children who were immunologically healthy with no underlying medical conditions 2023.

Deaths from varicella

Occasionally, complications of varicella can be fatal; mortality rates from identified European studies are shown in Table S1 (Additional file 1) 171819202122232425262728293031. Of 13 varicella-related deaths reporting in children aged 9 months to 9 years, during the 2006 to 2007 varicella season in England, Scotland and Wales, 12 occurred in immunologically healthy children 59. Eight children died following catastrophic deterioration over less than 24 hours; group A streptococcal sepsis was confirmed in five children and Staphylococcus aureus sepsis in two children 59. Other potentially fatal complications of varicella in children include pneumonia and myocarditis 60.

The risk of death from varicella is much higher (25- to 174-fold) in adults than in children 1761. As in children, the majority of adult deaths from varicella occur in previously healthy individuals, although underlying medical conditions, often immune suppression, contribute to a fatal outcome in some cases 17.

Varicella during pregnancy

Varicella is a serious infection in pregnancy, estimated to affect about 2,000 pregnancies each year in the UK 62. If left untreated, pregnant women are at greater risk of varicella pneumonia (occurring in about 9% of pregnant women with varicella) 63. Varicella may also cause complications in the infant caused by intrauterine infection with VZV via placental transmission at any stage of pregnancy. Intrauterine infection of the foetus in the early stages of development may result in congenital varicella syndrome (an incidence of about 2% after maternal varicella in the first 20 weeks of gestation 64), characterised by skin lesions with a dermatomal distribution, neurological defects, ocular disease and skeletal abnormalities 64. If the mother develops a varicella rash during the period from 4 days before to 2 days after delivery the infant is at risk of neonatal varicella 65. If left untreated, generalised neonatal varicella can lead to death in about 20% of cases. The serious consequences of varicella during pregnancy and the increased risk of herpes zoster for the child can be minimised by appropriate diagnosis and by using currently available immunoprophylactic and therapeutic interventions 66.

Herpes zoster

Following primary infection with VZV, the virus enters a period of latency within the dorsal root ganglia of the nervous system. The latent virus can be reactivated with neuronal transfer to the skin manifesting as herpes zoster. The mechanism of VZV reactivation is poorly understood, but several potential risk factors have been identified 67. The incidence of herpes zoster increases sharply from 50 to 60 years of age, increasing into later life 68. Although several studies have shown higher rates of reactivation in immunocompromised patients 67, recent reports suggest that herpes zoster predominantly affects immunologically healthy individuals 5869.

Initially, herpes zoster manifests as a characteristic rash accompanied by acute pain; however, further complications occur in 21 to 48% of patients 58. The most common and feared complication of herpes zoster is chronic neuropathic pain, known as post-herpetic neuralgia (PHN) 68. PHN occurs more frequently with advancing age and is estimated to affect half of patients with herpes zoster aged 70 years or older 70. It can persist for many years and may have a profound negative effect on patient quality of life, substantially interfering with physical, emotional and social functioning, vitality and mental health 687172.

Current status of varicella vaccination in Europe

The clinical burden of varicella in Europe demonstrates a medical need for prevention strategies against the disease. However, existing recommendations for varicella vaccination in Europe vary widely between countries (Table S3 in Additional file 1) 6737475.

Germany has the widest experience with varicella URV in Europe since use of the monovalent vaccine was recommended by the Ständigen Impfkommission of the Robert Koch-Institut in July 2004 5. From 2006, the combined MMRV vaccine was included in the German childhood immunisation calendar as a two-dose schedule to be used in place of MMR and varicella vaccines at the physician's discretion 76. Preliminary reports are now emerging on the impact of varicella vaccination in Germany. Data from a nationwide sentinel surveillance system showed that between April and September 2005, and April and September 2007 the average number of varicella cases reported per physician declined from 17 to 9 cases, corresponding with an increase in vaccine doses administered from 32 to 62 doses per physician 77. A decline in varicella-related complications was also observed 77. The reduction in the number of varicella cases and complications was noted in all age groups, but was most pronounced in infants aged 1 to 2 years. These early findings support previous estimates from epidemiological and economic modelling suggesting that varicella URV would be a highly efficient strategy in Germany to reduce the burden of varicella, resulting in benefits for both the individual and society 7879.

The majority of European countries with a national recommendation for varicella vaccination suggest targeted vaccination in susceptible adolescents or high-risk groups, such as seronegative women of childbearing age, healthcare workers, susceptible individuals with immunosuppressed close contacts, day-care personnel and teachers (Table S3 in Additional file 1). However, this strategy does not have the potential to interrupt viral transmission and, in the past, has been far less effective in achieving high coverage rates when compared with childhood programmes 74.

How can varicella vaccination be implemented in Europe?

Given that monovalent varicella vaccines have been available in Europe for more than 20 years, there has already been much debate on how best to introduce varicella vaccination. After consideration of the issues surrounding European varicella epidemiology, the Working Against Varicella in Europe group (then known as EuroVar) published a consensus statement in 2004. This statement recommended varicella vaccination for all children between 12 and 18 months of age, and to older, susceptible individuals if high coverage can be rapidly achieved 80. The health and economic benefits of varicella vaccination have also been recognised by the Society of Independent European Vaccination Experts who have recently recommended that immunisation of susceptible adolescents should be urgently implemented 74. However, the Society cautions that URV, preferably incorporating a two-dose schedule, will be needed to finally reduce the burden of varicella disease. The dramatic reduction in varicella morbidity and mortality rates observed in the USA following varicella URV has also led some experts to suggest that a universal varicella vaccination policy may be most appropriate for Europe, not just for the medical benefits that it would provide, but also for its social and economic advantages 81.

The long-awaited availability of MMRV vaccines has reinitiated discussions on how varicella vaccination can be implemented. The EuroVar consensus statement recognised that high coverage rates for varicella vaccination are more likely to be achieved if the vaccine was combined with the existing measles-mumps-rubella (MMR) vaccine (that is, as a tetravalent MMRV vaccine) 80. Indeed, EuroVar stated that the MMRV vaccine will not only enhance the implementation of varicella URV, but represents the way forward, providing a more convenient method of administration of the vaccine to children. Since 2006, two MMRV vaccines have been licensed in Europe – Priorix-Tetra™ and ProQuad®. Both vaccines are immunogenic with similar reactogenicity profiles compared with established MMR and varicella vaccines 8283.

Varicella universal routine vaccination vs. no vaccination

In countries where varicella URV has been implemented, it has proven a highly effective strategy for reducing the number of varicella cases, hospitalisations, ambulatory visits and deaths 118485. Using German epidemiological data from an age-structured dynamic infectious disease model (based on a birth cohort of 800,000 individuals), the likely consequences of delaying decisions on varicella vaccination for 1 year are 739,000 cases of varicella, 39,720 complicated cases, 5,740 hospitalisations and 22 deaths 86.

Routine childhood varicella vaccination vs. adolescent/adult varicella vaccination

Vaccination of susceptible adolescents from age 11 to 12 years onwards is an attractive option for healthcare payers. This strategy can prevent the elevated morbidity and mortality of varicella in older age groups, create a cohort of individuals less likely to develop herpes zoster later in life, mitigate the theoretical increase in herpes zoster with varicella URV and minimise the risk of a potential upward age-shift on the peak incidence of the disease (discussed later) 74. It could also reduce the risk of congenital varicella syndrome and neonatal varicella by protecting women of childbearing age 74. In some areas of Southern Europe, it has been suggested that vaccination of adolescents could be based on a negative history for varicella in place of serological testing for varicella antigens, thus minimising the cost of this strategy 52. For example, in Greece, where a high proportion of adolescents (21.5%) are still susceptible to varicella, a self-reported history was reported to have a high negative predictive value (73.5%), except in adolescents with household exposure to VZV 52.

Some caveats exist with an adolescent/adult varicella vaccination strategy. Adolescents, as a group, do not routinely visit a physician and coverage achieved for vaccines recommended in this age group is generally low 87. Varicella vaccination uptake in adolescents could be improved in some countries by catch-up programmes (that is, opportunistic vaccination). However, this approach may not work well in countries that do not include varicella vaccine in the national immunisation calendar as physicians will not be familiar with the vaccine.

An adolescent vaccination strategy is likely to be beneficial from an individual's perspective, estimated to prevent around 5% of varicella cases, 5% of complications, 8% of hospitalisations and 9% of deaths from varicella (assuming vaccination of 11 to 12 year-olds, with coverage rising from 10% to 30% over the first 5 years of a vaccination programme) 88. However, from a societal perspective, an adolescent strategy would have minimal effect on transmission of VZV and no benefit in the youngest infants (that is, younger than 1 year of age with a high risk of complications post-varicella) 74. A universal childhood varicella immunisation programme implemented in such a way that a high coverage rate is achieved 88, could address these issues and would have maximal impact on disease epidemiology, as has been demonstrated from data in the USA and Uruguay 11858990.

Monovalent varicella vaccination vs. tetravalent MMRV vaccination of infants and children

MMRV vaccines avoid the need for an additional injection when vaccinating against measles, mumps, rubella and varicella, which is beneficial for the majority of European countries that have an already crowded vaccination schedule and where administration of more than two vaccines in a single visit is usually not acceptable to parents or carers. URV with MMRV vaccines is likely to rapidly improve the uptake of varicella vaccination, in line with the coverage expected for MMR vaccines, thus maximising herd immunity and reducing the risk of an upward shift in the peak age of varicella disease. In addition to these benefits, two doses of MMRV vaccine will naturally facilitate a two-dose varicella vaccination schedule. MMRV vaccines are used in several countries such as the USA, Germany and Australia, and data demonstrating their effectiveness are eagerly awaited.

The recommendation by the USA Advisory Committee on Immunization Practices (ACIP) for two doses of varicella-containing vaccine as part of routine childhood immunisation, officially adopted in 2007, stated a preference for MMRV vaccines over the component MMR and varicella vaccines 10. However, ACIP removed the preference for the combination MMRV vaccine in 2008 91, in response to new data from surveillance by the Centers for Disease Control (CDC) and Merck for ProQuad® in the USA. These data suggested that the risk of febrile seizures in the 5 to 12 days after vaccination with the first dose of MMRV is higher than with separately administered MMR and varicella vaccines 92. Of note, febrile seizures are typically of short duration (< 15 minutes) and resolve without sequelae. Furthermore, the USA Food and Drug Administration continue to be satisfied with the safety and efficacy of MMRV vaccine, having not made any changes to its indications for use and stating that the benefits of using the vaccine continue to outweigh the risks 93. The situation with regard to MMRV vaccination and febrile seizures continues to be monitored closely. Data are not yet available for GlaxoSmithKline's MMRV vaccine and it is currently unclear what these data may show; the two vaccines differ in terms of measles and varicella dose.

A third option for introduction of varicella vaccination that may be considered by policy makers is to administer the first doses of MMR and varicella vaccines separately, followed by a second dose of combined MMRV vaccine at least 4 weeks later 9495. This strategy may mitigate any perceived increase in reactogenicity following the first dose of MMRV vaccine.

Two doses of varicella vaccine vs. one dose for universal routine vaccination

Two doses of varicella vaccine as part of the USA childhood immunisation programme have been officially recommended by the ACIP since 2007 10. Regulatory approval of MMRV vaccines by the European Medicines Agency also recognises that a second dose of a varicella-containing vaccine ensures maximal protection against the disease 96. In Europe, two doses of varicella vaccine are recommended in Greece (Table S3 in Additional file 1) and by the Spanish Association of Pediatrics (although this has yet to be officially adopted by the national authorities 97), and in Germany, MMRV vaccine can be used, resulting in two doses of varicella being given.

Countries considering varicella URV (with monovalent or combined vaccines) have the opportunity to evaluate the merits of a one- or two-dose schedule. In the USA, after a rapid decline in varicella incidence following the introduction of a one-dose vaccination strategy from 1995, the number of cases at CDC surveillance sites reached a plateau in 2002. This occurred despite continued high rates of vaccination coverage 98. Furthermore, outbreaks of breakthrough varicella (that is, a case of varicella occurring 42 days or more after vaccination following exposure to wild-type virus) continued to occur among immunised children in day-care centres and schools (see recent review by Seward et al.) 99. Most studies in this review showed a varicella vaccine effectiveness of 80 to 89% after one dose 99, thus leaving 10 to 20% of vaccinees who either did not respond to vaccination (primary immune failure) or who experienced waning immunity over time (secondary immune failure) 100. Two doses of varicella vaccine have been associated with higher vaccine efficacy in clinical studies and the projected risk of breakthrough disease over 10 years is three times lower than among individuals who received one dose 101. Humoral and cell-mediated responses were also greater after two doses of varicella vaccine, suggesting improved vaccine efficacy compared with one dose 102103.

The interval between two doses of varicella vaccine (monovalent or MMRV)

Depending on the product used, the first dose of monovalent varicella vaccine or MMRV vaccine can be administered from the age of 9 or 12 months. The second dose is then administered according to an 'accelerated', 'standard' or 'longer' schedule in accordance with local recommendations. The schedules currently used for MMR vaccines are shown in Table S3 (Additional file 1) 104. Each strategy is associated with specific benefits and challenges, which are discussed below. For the MMRV vaccine, only the varicella component is discussed – there may be different benefits and challenges for the measles, mumps and rubella components.

Accelerated schedule: dose 1 at 11 to 23 months and dose 2 at 12 to 24 months

An accelerated schedule means that the two vaccine doses are administered close together (at least 1 month apart; during second year of life for MMR(V) vaccines). This schedule is used for MMR vaccines in Europe in the Czech Republic, Austria, France, Germany and Switzerland 104, and for MMRV vaccines in Germany (Table S3 in Additional file 1) 76. In the USA, although the recommended timing of the second dose is 4 to 6 years of age, this remains flexible, permitting an accelerated schedule 10, and it is also allowed by the WHO for measles-containing vaccines depending on the local programmatic and epidemiological situation 105.

Administering two doses of varicella-containing vaccine with a short interval provides the opportunity to enhance compliance, and hence vaccine coverage because 2-year-old or younger children are more accessible to healthcare professionals than older age groups. After one dose of vaccine, the risk of breakthrough varicella increases with time. Administering MMRV vaccines according to an accelerated schedule therefore allows high levels of immunity to vaccine antigens to be established early in life, ensuring that, if primary vaccine failure occurs, a child does not remain unprotected for 2 to 12 years (standard and longer schedules).

Clinical studies of varicella and MMRV vaccines show robust and persistent immune responses when two doses are administered according to an accelerated schedule 8283101106. In one study, in which children were randomised to receive either two doses of MMRV vaccine (Priorix-Tetra™; MMRV group) or one dose of MMR vaccine (Priorix™) concomitantly with varicella vaccine (Varilrix™) followed by another MMR vaccination 6 to 8 weeks apart (MMR+V group) 82, seropositivity rates for varicella after 3 years were 99.4% (MMRV group, N = 225) and 96.8% (MMR+V group, N = 79) 106. Over the 3-year follow-up period (total vaccinated cohort N = 494), two mild varicella breakthrough cases were reported in the MMRV group and four mild and one moderate case in the MMR+V group 106. No studies evaluating the immune response of two doses of Merck's MMRV vaccine administered according to an accelerated schedule could be identified.

Standard schedule: dose 1 at 12 to 24 months and dose 2 at 3 to 7 years

A standard schedule with an interval of 1 to 6 years is used for administration of MMR vaccines in the majority of countries in Europe (Table S3 in Additional file 1). In some countries, such as Finland, excellent coverage has been achieved with both vaccine doses, which would be beneficial for varicella vaccination should MMR vaccines be replaced with MMRV vaccines 107. As for the accelerated schedule, a robust immune response was measured to the second dose of MMRV vaccine given to children at 5 to 6 years 108.

A potential drawback of the standard schedule is the risk of breakthrough disease during the longer interval between vaccine doses. One dose of varicella vaccine was shown to be 80 to 85% effective in a number of field studies, which is not sufficient to prevent outbreaks and interrupt viral transmission 99. Thus, in the intervening 1 to 6-year period between the two doses, breakthrough cases of varicella can be expected, which could result in outbreaks in close communities such as day-care centres and schools, and cases in susceptible adolescents and adults. However, given the potential scheduling challenges with administering the vaccine according to an accelerated schedule (for example, crowded vaccination calendars during the first 2 years of life), the standard schedule offers an effective alternative.

Longer schedule: dose 1 at 12 to 18 months and dose 2 at 8 to 13 years

Several countries administer MMR vaccines according to a longer schedule, which means that the two doses are given 7 to 12 years apart (Table S3 in Additional file 1). Administering the second dose of varicella-containing vaccine with a long interval is likely to reduce the risk of waning immunity to vaccine antigens resulting in infection into adolescence and adulthood, when the disease can be more severe 100. However, as was seen from experiences in the USA, the risk of breakthrough disease between vaccine doses may prevent elimination of varicella. Despite this potential drawback, countries may be hesitant about changing an established longer schedule for fear of a negative impact on vaccine uptake.

Why has varicella vaccination been delayed in Europe?

There are positive effects of universal childhood varicella vaccination on disease incidence, and the rate of complications and hospitalisations 84. Given these benefits, it is curious why more countries in Europe have not introduced the varicella vaccine into national immunisation schedules. The possible reasons for this are considered in brief below.

Lack of recognition of varicella as a serious disease

As noted previously, appreciation of the true burden of varicella can be hampered because varicella is not a notifiable disease in many countries, and there appears to be a degree of underreporting to mandatory notification systems. A lack of awareness about the potential complications of varicella means that the disease continues to be perceived as benign by many physicians and parents.

The available reports of the varicella burden in European countries indicate that children can experience complications of this disease, which may require hospitalisation, and occasionally can be fatal. Communication of varicella outbreaks, such as the large outbreak in the UK in April 2007, may be beneficial in raising awareness of the disease among parents, physicians and public health officials.

Perception of age shift with varicella vaccines

A concern exists that widespread childhood varicella vaccination may produce an upward shift in the peak age of the disease to older individuals, for whom varicella may be more severe. In the USA there has, as anticipated, been a rise in the age of peak incidence of the disease following the widespread introduction of varicella vaccination with a one-dose schedule. Before 1995, around 73% of varicella cases occurred in children aged 6 years or younger, with a peak disease frequency between 3 and 6 years 100. In 2004, on the other hand, children aged 6 years and younger accounted for only 30% of varicella cases 100; disease frequency peaked in vaccinated children (one dose) between the ages of 6 and 9 years and in unvaccinated children between the age of 9 and 12 years 100. However, the absolute number of cases in older children remained similar to that reported in the pre-vaccination era. Conversely, since URV implementation there has been a decline in the age-specific hospitalisation or varicella incidence rates in all age groups (including infants not eligible for vaccination and adults) 1190109. This observation is most likely explained by herd immunity, where high coverage rates interrupt viral transmission, indirectly protecting those who are not vaccinated.

Perception of an increase in herpes zoster

A number of sources indicate that boosting of immunity to VZV can reduce the incidence of herpes zoster 67110. A case-control study suggested that exogenous exposure to VZV via contact with children protects individuals with latent VZV infection against herpes zoster by boosting immunity 111. Statistically significant protection (odds ratio 0.29 (95% confidence interval: 0.10 to 0.84)) was achieved for those adults with five or more contacts with VZV during the past 10 years 111. This type of data led to formulation of the hypothesis that a reduction of childhood varicella by vaccination might lead to increased incidence of herpes zoster in adults 110. Using mathematical modelling, Brisson et al proposed that routine varicella vaccination of children will produce a substantial increase in the rates of herpes zoster over the first 30 to 50 years after vaccination is introduced 110. In the longer term, under the assumptions of the model, a vaccination programme that eliminates varicella will also eliminate herpes zoster 110. To date, the majority of studies conducted in countries where the incidence of varicella has been reduced by vaccination have not shown an accompanying increase in herpes zoster 84109112113.

Evidence from different sources suggests that varicella vaccination may be associated with a reduced incidence, and hence lower risk, of herpes zoster in vaccinees 113114115116. In a 10 to 26-year follow-up of individuals vaccinated as healthy young adults, the herpes zoster incidence was 0.91/1,000 person-years, lower than the rates quoted by the authors for unvaccinated individuals (2.15 to 4.05 cases/1,000 person-years) 113. Furthermore, children with leukaemia (who have a naturally increased risk of herpes zoster), who were vaccinated with one dose of varicella vaccine, had a lower incidence of herpes zoster than children with leukaemia who contracted VZV naturally (crude incidence rates of 8.0 vs. 24.6/1,000 person-years, respectively; P = 0.01) 114.

Available data support the hypothesis that vaccination may reduce viral latency and thus the incidence of herpes zoster by minimising infection of the skin (that is, the development of varicella lesions) 115, which is thought to be directly related to the establishment of VZV latency 114115.

In summary, the childhood vaccination programme should reduce the risk of herpes zoster in vaccinees in the longer term. Furthermore, if needed, appropriate action can be taken (for example, implementation of a herpes zoster vaccine in adults).

Achieving high coverage rates

If varicella vaccination is to be implemented using MMRV vaccines, the existing coverage for MMR vaccines may need to be considered. The WHO recommendations state that coverage rates for varicella vaccination should exceed 85% in order to avoid an upward age-shift in the peak incidence of varicella disease. In European Union countries in 2006, coverage for measles-containing vaccine ranged from 82% to 98% for the first dose, with 18 of 20 countries with data available reporting coverage rates to the WHO exceeding 85% 117. For the second dose, vaccine coverage ranged from 60 to 98%, with 11 of 14 countries reporting coverage rates to the WHO exceeding 85% 117. Therefore, the majority of European countries with data available reach the stated threshold of 85% coverage with MMR vaccines, and thus could be considered suitable for implementation of MMRV vaccines.

Cost (country-specific)

The cost of vaccination is relevant for public health officials and individuals purchasing vaccines on the private market, and is country-specific. European countries apply different models for production of guidelines, and for linking these to funding, but cost-effectiveness is becoming a standard requirement. In some countries, such as the UK and France, only costs from a healthcare perspective are taken into account when considering the cost-effectiveness of vaccination – all societal costs (for example, work-time lost) are excluded from the analysis.

In Germany, findings from a mathematical model suggest that varicella URV with a one-dose schedule will provide essential clinical benefits for individuals, and that significant economic benefits can also be expected 35. Furthermore, an updated version of this model has assessed the direct and indirect cost-savings associated with two doses of varicella vaccine and MMRV vaccination compared with an adolescent immunisation strategy with one dose of varicella vaccine 118. The model demonstrated that two doses of MMRV vaccine are cost-saving from a societal and a health system perspective (benefit-cost-ratios [BCR] of 2.56 and 1.08, respectively) 118. Using the same model, varicella URV with a two-dose schedule was predicted to be highly effective for reducing the burden of varicella disease in Italy, with significant net savings from the societal perspective, but was not cost-saving from the National Health Service perspective in the majority of situations analysed 119.

The latest study results from the USA demonstrated that, compared with no intervention, the two-dose regimen is cost-saving from a societal perspective (BCR = 2.73) (assuming that 30% of children would receive MMRV vaccine as a first dose and 100% would receive MMRV as a second dose, and using 2006 prices) 120. Furthermore, the economic benefit of the two-dose MMRV regimen compares very favourably with other medical interventions. However, the authors note that compared with one-dose URV, the two-dose MMRV regimen did not produce additional savings from a societal perspective (BCR = 0.56). Notably, however, additional factors such as the cost associated with outbreaks following one-dose URV were not included in the model.

A favourable BCR does not necessarily result in public funding of a vaccine. New vaccines entering the market compete for a share of a limited healthcare budget; in recent years, state-of-the-art vaccines against Streptococcus pneumoniae, human papilloma virus and rotavirus have commanded a great deal of public attention and, in some countries, have been prioritised over varicella vaccination.

Summary

Despite European recommendations for varicella vaccination, VZV continues to cause a high number of varicella cases, potentially requiring medical visits or hospitalisations and occasionally leading to long-term sequelae or even death. The majority of varicella complications occur in healthy children, meaning that it is not possible to predict who will be affected.

With the exception of Germany and Greece, most European countries have delayed the introduction of varicella vaccination into the national immunisation schedule. However, with many concerns about the vaccine remaining hypothetical and the new opportunities offered by MMRV vaccines, reassessment may be timely.

Accumulating evidence from countries that have implemented universal varicella vaccination of infants demonstrates a dramatic reduction in the burden of varicella, thus providing the strongest support for widespread implementation of the WHO recommendation for varicella vaccination in European countries.

Competing interests

All authors are members of the Working Against Varicella in Europe (WAVE) group. Meetings of this group and the development of this manuscript were supported by an unrestricted educational grant from GlaxoSmithKline Biologicals. PB has participated in the activities of expert groups and boards on vaccines and vaccination policies sponsored by different pharmaceutical companies. JB receives research funding and sponsorship for attending advisory board meetings from GlaxoSmithKline, Merck and Sanofi Pasteur MSD. AG consults and lectures on varicella and zoster vaccines for GlaxoSmithKline and Merck, and also receives research funding from GlaxoSmithKline and Merck. HR/Vaxinostics has performed clinical studies with MMR-varicella vaccines for GSK and Sanofi Pasteur MSD. CWO has participated as an expert in different temporary groups for vaccine manufacturers. PW has been a consultant to GlaxoSmithKline and Sanofi Pasteur MSD, has served on advisory boards for vaccine manufactures and holds a number of shares in GlaxoSmithKline. The following authors declare no other competing interests: MG, WH, VP, BR, CSD, and JS.

Authors' contributions

All authors contributed to the manuscript by discussing the challenges facing European countries when deciding whether to introduce varicella vaccination, as well as the advantages and disadvantages of different vaccination schedules for monovalent and combined MMRV vaccines at three meetings of the WAVE (Working Against Varicella in Europe) group held in Belgium, Ireland and the Netherlands in December 2007, June 2008 and December 2008, respectively. The WAVE group comprises experts with considerable experience in all aspects of vaccinology, particularly varicella, from 10 European countries (Belgium, Finland, France, Germany, Greece, Italy, Poland, Spain, Netherlands and the UK) and from the USA.

Following the first meeting, a number of resources were searched for articles of relevance to obtain information on the epidemiology of varicella in Europe, including PubMed (using the terms 'MMR', 'MMRV', 'varicella' and 'chickenpox'), respected websites (for example, WHO and CDC) and abstracts from paediatric congresses (for example, European Society for Paediatric Infectious Diseases, International Congress on Infectious Diseases, International Disease Society of America and the World Society for Paediatric Infectious Diseases). Additional information sources were identified from the bibliographies of these references or from the authors' own libraries (national data) and expertise.

The first draft manuscript was prepared by a scientific writer (Dr Alison Lovibond), with contribution from all authors via electronic discussions and face-to-face meetings. The final manuscript was read and approved by all authors.

Acknowledgements

The authors would like to thank Alison Lovibond who provided medical writing assistance on behalf of Fishawack Communications Ltd. Development of the manuscript was supported by GlaxoSmithKline Biologicals. Priorix, Priorix-Tetra and Varilrix are trademarks of the GlaxoSmithKline group of companies. ProQuad, M-M-RII and Varivax are trademarks of Merck & Co, Inc.

<p>Varicella</p> Heininger U Seward JF Lancet 2006 368 1365 1376 10.1016/S0140-6736(06)69561-5 17046469 <p>The WHO position paper on varicella vaccines</p> World Health Organization Wkly Epidemiol Rec 1998 73 241 248 9715106 <p>Varicella vaccination in Australia and New Zealand</p> Macartney KK Burgess MA J Infect Dis 2008 197 Suppl 2 S191 195 10.1086/522157 18419396 <p>National Advisory Committee on Immunization (NACI) update on varicella</p> National Advisory Committee on Immunization Can Commun Dis Rep 2004 30 1 26 <p>Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2006</p> Robert Koch Institut Epidemiol Bulletin 2006 30 235 254 <p>Childhood immunisation calendar, Greece</p> http://www.mohaw.gr/gr/thefuture/anakoinoseis/Timetable%202008.xls <p>WHO vaccine preventable disease monitoring system: Immunization schedules by antigen, selection centre</p> http://www.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm <p>Varicella vaccination in Japan, South Korea, and Europe</p> Sadzot-Delvaux C Rentier B Wutzler P Asano Y Suga S Yoshikawa T Plotkin S J Infect Dis 2008 197 Suppl 2 185 190 10.1086/522163 <p>Survey of the status of self-paid varicella vaccination among children one to six years of age in Taiwan</p> Liao SL Huang T Huang YC Jiang DD J Microbiol Immunol Infect 2007 40 112 115 17446958 <p>Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)</p> Marin M Guris D Chaves SS Schmid S Seward JF MMWR 2007 56 1 40 17585291 <p>Impact of universal varicella vaccination of one year-olds in Uruguay: 1997–2005</p> Quian J Ruttimann R Romero C Dall'orso P Cerisola A Breuer T Greenberg M Verstraeten T Arch Dis Child 2008 93 845 850 2563416 18456699 10.1136/adc.2007.126243 <p>Varicella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997–2004</p> Perez-Farinos N Ordobas M Garcia-Fernandez C Garcia-Comas L Canellas S Rodero I Gutierrez-Rodriguez A Garcia-Gutierrez J Ramirez R BMC Infect Dis 2007 7 59 1913920 17570859 10.1186/1471-2334-7-59 <p>Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention</p> Centers for Disease Control and Prevention MMWR 1996 45 1 36 <p>Epidemiology of varicella hospitalizations in the United States, 1995–2005</p> Reynolds MA Watson BM Plott-Adams KK Jumaan AO Galil K Maupin TJ Zhang JX Seward JF J Infect Dis 2008 197 Suppl 2 S121 131 <p>Varicella-related deaths – United States, January 2003–June 2004</p> Centers for Disease Control and Prevention MMWR 2005 54 272 274 15788992 <p>Varicella</p> Centers for Disease Control and Prevention Epidemiology and Prevention of Vaccine-Preventable Diseases Washington DC: Public Health Foundation Atkinson WHJ, McIntyre L, Wolfe S 10 2006 13 171 192 <p>Varicella in non-immune persons: incidence, hospitalization and mortality rates</p> Boelle PY Hanslik T Epidemiol Infect 2002 129 599 606 10.1017/S0950268802007720 12558344 <p>Épidémiologie de la varicelle en France</p> Bonmarin B Ndiaye B Seringe E Levy-Bruh D Bull Epidemiol Hebd 2005 8 29 32 <p>Evaluation of varicella complications through a retrospective hospital survey in a paediatric center over 16 years in France</p> Mallet E Maitre M Delalande-Dutilleul L Marguet C Mouterde O Arch Pediatr 2004 11 1145 1151 15351011 <p>The burden of varicella complications before the introduction of routine varicella vaccination in Germany</p> Liese JG Grote V Rosenfeld E Fischer R Belohradsky BH v Kries R Pediatr Infect Dis J 2008 27 119 124 10.1097/INF.0b013e3181586665 18227713 <p>Varicella-related complications and hospitalisations in a tertiary pediatric medical center before vaccine introduction</p> Theodoridou M Laina I Hadjichristodoulou C Syriopoulou V Eur J Pediatr 2006 165 273 274 10.1007/s00431-005-0043-6 16450160 <p>Severe complications of chickenpox in hospitalised children in the UK and Ireland</p> Cameron JC Allan G Johnston F Finn A Heath PT Booy R Arch Dis Child 2007 92 1062 1066 10.1136/adc.2007.123232 17991685 <p>Epidemiology of hospital admissions for chickenpox in children: an Italian multicentre study in the pre-vaccine era</p> Marchetto S de Benedictis FM de Martino M Versace A Chiappini E Bertaine C Osimani P Cordiali R Gabiano C Galli L Acta Paediatr 2007 96 1490 1493 10.1111/j.1651-2227.2007.00465.x 17880417 <p>The epidemiology of varicella and herpes zoster in the Netherlands: implications for varicella zoster virus vaccination</p> de Melker H Berbers G Hahne S Rumke H Hof van den S de Wit A Boot H Vaccine 2006 24 3946 3952 10.1016/j.vaccine.2006.02.017 16564115 <p>Varicella zoster virus (VZV) infection</p> Boot H Zanden van der B van Lier A Maas van der N De Melker H The National Immunisation Programme in the Netherlands: developments in 2007 National Institute for Public Health and the Environment de Melker H, Kramer M 2008 <p>Surveillance of varicella and herpes zoster in Slovenia, 1996 – 2005</p> Socan M Blasko M Euro Surveill 2007 12 <p>Epidemiology of primary varicella hospitalizations in Spain</p> Gil A Oyaguez I Carrasco P Gonzalez A Vaccine 2002 20 295 298 10.1016/S0264-410X(01)00370-X <p>The burden of severe varicella in Spain, 1995–2000 period</p> Gil A Gonzalez A Oyaguez I Martin MS Carrasco P Eur J Epidemiol 2004 19 699 702 10.1023/B:EJEP.0000036791.43264.84 15461202 <p>Epidemiology of severe varicella-zoster virus infection in Spain</p> Gil A San-Martin M Carrasco P Gonzalez A Vaccine 2004 22 3947 3951 10.1016/j.vaccine.2004.04.004 15364443 <p>Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents</p> Bonhoeffer J Baer G Muehleisen B Aebi C Nadal D Schaad UB Heininger U Eur J Pediatr 2005 164 366 370 10.1007/s00431-005-1637-8 15747132 <p>Deaths from chickenpox in England and Wales 1995–7: analysis of routine mortality data</p> Rawson H Crampin A Noah N BMJ 2001 323 1091 1093 59681 11701571 10.1136/bmj.323.7321.1091 <p>Epidemiology of hospital admissions for paediatric varicella infections: a one-year prospective survey in the pre-vaccine era</p> Dubos F Grandbastien B Hue V Martinot A Epidemiol Infect 2007 135 131 138 10.1017/S0950268806006467 16740185 <p>ENVOL study on the medical management of varicella and its complications in French ambulatory care</p> Emery C Lancon F Fagnani F Pechevis M Durand I Floret D Med Mal Infect 2006 36 92 98 16460897 <p>Paediatric varicella hospitalisations in France: a nationwide survey</p> Grimprel E Levy C de La Rocque F Cohen R Soubeyrand B Caulin E Derrough T Lecuyer A d'Athis P Gaudelus J Clin Microbiol Infect 2007 13 546 549 10.1111/j.1469-0691.2007.01706.x 17378927 <p>Empirical data on the varicella situation in Germany for vaccination decisions</p> Wagenpfeil S Neiss A Banz K Wutzler P Clin Microbiol Infect 2004 10 425 430 10.1111/j.1469-0691.2004.00853.x 15113320 <p>Severe complications of varicella in previously healthy children in Germany: a 1-year survey</p> Ziebold C von Kries R Lang R Weigl J Schmitt HJ Pediatrics 2001 108 E79 10.1542/peds.108.1.79 11694663 <p>The epidemiology of varicella in school-aged Greek children before the implementation of universal vaccination</p> Katsafadou A Ferentinos G Constantopoulos A Papaevangelou V Eur J Clin Microbiol Infect Dis 2008 27 223 226 10.1007/s10096-007-0418-x 18026762 <p>Pediatric sentinel surveillance of vaccine-preventable diseases in Italy</p> Ciofi Degli Atti ML Salmaso S Bella A Arigliani R Gangemi M Chiamenti G Brusoni G Tozzi AE Pediatr Infect Dis J 2002 21 763 768 10.1097/00006454-200208000-00013 12192166 <p>Reports on cases of infectious diseases and poisonings in Poland – 2006</p> http://www.pzh.gov.pl/oldpage/epimeld/2006/index_ma.html <p>Varicella in Romania: epidemiological trends, 1986–2004</p> Arama V Rafila A Streinu-Cercel A Pistol A Bacruban R Sandu R Pitigoi D Negoita A Euro Surveill 2005 10 E050811 050816 16785684 <p>Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study</p> Diez-Domingo J Aristegui J Calbo F Gonzalez-Hachero J Moraga F Pena Guitian J Ruiz Contreras J Torrellas A Vaccine 2003 21 3236 3239 10.1016/S0264-410X(03)00264-0 12804853 <p>Hospital admissions for varicella complications in children aged less than 15 years old</p> Perez-Yarza EG Arranz L Alustiza J Azkunaga B Uriz J Sarasua A Mendiburu I Emparanza JI An Pediatr (Barc) 2003 59 229 233 10.1157/13050601 12975114 <p>Epidemiology of varicella-zoster virus in England and Wales</p> Brisson M Edmunds WJ J Med Virol 2003 70 Suppl 1 S9 14 10.1002/jmv.10313 12627480 <p>The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region</p> Nardone A de Ory F Carton M Cohen D van Damme P Davidkin I Rota MC de Melker H Mossong J Slacikova M Tischer A Andrews N Berbers G Gabutti G Gay N Jones L Jokinen S Kafatos G de Aragon MV Schneider F Smetana Z Vargova B Vranckx R Miller E Vaccine 2007 25 7866 7872 10.1016/j.vaccine.2007.07.036 17919788 <p>Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data</p> Aebi C Fischer K Gorgievski M Matter L Muhlemann K Vaccine 2001 19 3097 3103 10.1016/S0264-410X(01)00035-4 11312004 <p>Seroprevalence and force of infection of varicella-zoster virus in Luxembourg</p> Mossong J Putz L Schneider F Epidemiol Infect 2004 132 1121 1127 10.1017/S0950268804002754 15635970 <p>Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes</p> Salleras L Dominguez A Vidal J Plans P Salleras M Taberner JL Vaccine 2000 19 183 188 10.1016/S0264-410X(00)00178-X 10930671 <p>The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium)</p> Thiry N Beutels P Shkedy Z Vranckx R Vandermeulen C Wielen MV Damme PV Eur J Pediatr 2002 161 588 593 10.1007/s00431-002-1053-2 12424583 <p>Seroprevalence of varicella-zoster virus in the German population</p> Wutzler P Farber I Wagenpfeil S Bisanz H Tischer A Vaccine 2001 20 121 124 10.1016/S0264-410X(01)00276-6 11567755 <p>Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey</p> Alp H Altinkaynak S Ertekin V Kilicaslan B Giiraksin A Health Policy 2005 72 119 124 10.1016/j.healthpol.2004.03.008 15760704 <p>The seroepidemiology of varicella in Italy</p> Gabutti G Penna C Rossi M Salmaso S Rota MC Bella A Crovari P Epidemiol Infect 2001 126 433 440 10.1017/S0950268801005398 11467800 <p>Presumptive varicella vaccination is warranted in Greek adolescents lacking a history of disease or household exposure</p> Katsafadou A Kallergi K Ferentinos G Goulioti T Foustoukou M Papaevangelou V Eur J Pediatr 2009 168 23 25 10.1007/s00431-008-0701-6 18392640 <p>Seroprevalence of varicella in the French population</p> Khoshnood B Debruyne M Lancon F Emery C Fagnani F Durand I Floret D Pediatr Infect Dis J 2006 25 41 44 10.1097/01.inf.0000195636.43584.bb 16395101 <p>The age of infection with varicella-zoster virus in St Lucia, West Indies</p> Garnett GP Cox MJ Bundy DA Didier JM St Catharine J Epidemiol Infect 1993 110 361 372 8386097 <p>Epidemiology of varicella zoster virus infection in Canada and the United Kingdom</p> Brisson M Edmunds WJ Law B Gay NJ Walld R Brownell M Roos L De Serres G Epidemiol Infect 2001 127 305 314 10.1017/S0950268801005921 11693508 <p>Changes in age-related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy</p> Kudesia G Partridge S Farrington CP Soltanpoor N J Clin Pathol 2002 55 154 155 1769589 11865016 <p>Epidemiology of chickenpox in France (1991–1995)</p> Deguen S Chau NP Flahault A J Epidemiol Community Health 1998 52 Suppl 1 S46 49 <p>A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction</p> Yawn B Saddier P Wollan P St Sauver J Kurland M Sy L Mayo Clin Proc 2007 82 1341 1349 10.4065/82.11.1341 17976353 <p>2006–7 chickenpox season: 13 childhood deaths in England, Scotland and Wales compared with averages of 4–8.7 per year in the United Kingdom: more evidence for routine introduction of the varicella vaccine?</p> Menson E Heath PT Lyall H Ramsay M Sinka K Miles J Fleming T Tong W Breuer J Nyman AG Arch Dis Child 2008 93 Suppl 1 A75 84 <p>Varicella-related deaths in children and adolescents – Germany 2003–2004</p> Grote V von Kries R Springer W Hammersen G Kreth HW Liese J Acta Paediatr 2008 97 187 192 10.1111/j.1651-2227.2007.00595.x 18076716 <p>Varicella mortality: trends before vaccine licensure in the United States, 1970–1994</p> Meyer PA Seward JF Jumaan AO Wharton M J Infect Dis 2000 182 383 390 10.1086/315714 10915066 <p>Epidemiology, outcome and control of varicella-zoster infection</p> Miller E Marshall R Rev Med Microbiol 1993 4 222 230 <p>Varicella pneumonia in adults</p> Mohsen AH McKendrick M Eur Respir J 2003 21 886 891 10.1183/09031936.03.00103202 12765439 <p>The congenital varicella syndrome</p> Sauerbrei A Wutzler P J Perinatol 2000 20 548 554 10.1038/sj.jp.7200457 11190597 <p>Neonatal varicella</p> Sauerbrei A Wutzler P J Perinatol 2001 21 545 549 10.1038/sj.jp.7210599 11774017 <p>Varicella-zoster virus infections during pregnancy: epidemiology, clinical symptoms, diagnosis, prevention and therapy</p> Sauerbrei A Wutzler P Curr Pediat Rev 2005 1 205 216 10.2174/157339605774574962 <p>What does epidemiology tell us about risk factors for herpes zoster?</p> Thomas SL Hall AJ Lancet Infect Dis 2004 4 26 33 10.1016/S1473-3099(03)00857-0 14720565 <p>The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine</p> Schmader K Gnann JW Watson P J Infect Dis 2008 197 Suppl 2 S207 215 10.1086/522152 18419399 <p>Immunocompetent children account for the majority of complications in childhood herpes zoster</p> Grote V von Kries R Rosenfeld E Belohradsky BH Liese J J Infect Dis 2007 196 1455 1458 10.1086/522631 18008223 <p>The burden of herpes zoster: a prospective population based study</p> Scott FT Johnson RW Leedham-Green M Davies E Edmunds WJ Breuer J Vaccine 2006 24 1308 1314 10.1016/j.vaccine.2005.09.026 16352376 <p>Characteristics of patients with herpes zoster on presentation to practitioners in France</p> Chidiac C Bruxelle J Daures JP Hoang-Xuan T Morel P Leplege A El Hasnaoui A de Labareyre C Clin Infect Dis 2001 33 62 69 10.1086/320884 11389496 <p>The cost of treatment for post-herpetic neuralgia in the UK</p> Davies L Cossins L Bowsher D Drummond M Pharmacoeconomics 1994 6 142 148 10.2165/00019053-199406020-00006 10147439 <p>Varicella vaccination overview in European countries</p> http://www.euvac.net/graphics/euvac/vaccination/var.html <p>Varicella vaccination in Europe: are we ready for a universal childhood programme?</p> Sengupta N Booy R Schmitt HJ Peltola H Van-Damme P Schumacher RF Campins M Rodrigo C Heikkinen T Seward J Jumaan A Finn A Olcen P Thiry N Weil-Olivier C Breuer J Eur J Pediatr 2008 167 47 55 10.1007/s00431-007-0424-0 17334784 <p>Soziale Pädiatrie und Jugendmedizin</p> Wutzler P Schmitt H-J Bisanz H Kinderärztliche Praxis 2008 79 75 77 <p>Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2007</p> Robert Koch Institut Epidemiol Bull 2007 30 267 286 <p>Varicella sentinel in Germany shows success of vaccination</p> Siedler A Arndt U 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 13–17 May; Graz, Austria 2008 <p>The cost-effectiveness of routine childhood varicella vaccination in Germany</p> Banz K Wagenpfeil S Neiss A Goertz A Staginnus U Vollmar J Wutzler P Vaccine 2003 21 1256 1267 10.1016/S0264-410X(02)00431-0 12559807 <p>Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis</p> Knuf M Neiss A Wutzler P Klin Padiatr 2006 218 203 212 10.1055/s-2005-836610 16819701 <p>A consensus paper: varicella vaccination of healthy children – a challenge for Europe</p> Rentier B Gershon AA the members of EuroVar the European Working Group on Varicella (EuroVar) Pediatr Infect Dis J 2004 23 379 389 10.1097/01.inf.0000122606.88429.8f 15131459 <p>Is Europe ready to embrace a policy of universal varicella vaccination?</p> Ramet J Weil-Olivier C Sedlak W Int J Clin Pract 2005 59 1326 1333 10.1111/j.1742-1241.2005.00647.x 16236088 <p>Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children</p> Knuf M Habermehl P Zepp F Mannhardt W Kuttnig M Muttonen P Prieler A Maurer H Bisanz H Tornieporth N Descamps D Willems P Pediatr Infect Dis J 2006 25 12 18 10.1097/01.inf.0000195626.35239.58 16395096 <p>Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad)</p> Kuter BJ Brown ML Hartzel J Williams WR EvesiKaren A Black S Shinefield H Reisinger KS Marchant CD Sullivan BJ Thear M Klopfer S Xu J Gress JO Schodel F Hum Vaccin 2006 2 205 214 17035730 <p>The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review</p> Reynolds MA Chaves SS Harpaz R AS L Seward JF J Infect Dis 2008 197 Suppl 2 S224 227 10.1086/522162 18419401 <p>Decline in mortality due to varicella after implementation of varicella vaccination in the United States</p> Nguyen HQ Jumaan AO Seward JF N Engl J Med 2005 352 450 458 10.1056/NEJMoa042271 15689583 <p>The burden of varicella in Germany: potential risks and economic impact</p> Banz K Wagenpfeil S Neiss A Hammerschmidt T Wutzler P Eur J Health Econom 2004 5 46 53 10.1007/s10198-003-0200-7 <p>Adolescent vaccination: coverage achieved by ages 13–15 years, and vaccinations received as recommended during ages 11–12 years, National Health Interview Survey 1997–2003</p> McCauley MM Stokley S Stevenson J Fishbein DB J Adolesc Health 2008 43 540 547 10.1016/j.jadohealth.2008.08.002 19027641 <p>Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany</p> Wutzler P Neiss A Banz K Goertz A Bisanz H Med Microbiol Immunol (Berl) 2002 191 89 96 10.1007/s00430-002-0123-4 <p>Varicella disease after introduction of varicella vaccine in the United States, 1995–2000</p> Seward JF Watson BM Peterson CL Mascola L Pelosi JW Zhang JX Maupin TJ Goldman GS Tabony LJ Brodovicz KG Jumaan AO Wharton M JAMA 2002 287 606 611 10.1001/jama.287.5.606 11829699 <p>Impact of varicella vaccination on health care utilization</p> Zhou F Harpaz R Jumaan AO Winston CA Shefer A JAMA 2005 294 797 802 10.1001/jama.294.7.797 16106004 <p>Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine</p> Centers for Disease Control and Prevention MMWR 2008 57 258 260 18340332 <p>Department of Health and Human Services Centers for Disease Control and Prevention Advisory Committee on Immunization Practices Summary report, 27–28 February 2008</p> http://www.cdc.gov/vaccines/recs/ACIP/downloads/min-feb08.pdf <p>FDA: information pertaining to labeling revision for ProQuad</p> http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm123798.htm <p>A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax</p> Reisinger KS Brown ML Xu J Sullivan BJ Marshall GS Nauert B Matson DO Silas PE Schodel F Gress JO Kuter BJ Pediatrics 2006 117 265 272 10.1542/peds.2005-0092 16452343 <p>Immunogenicity and safety of measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age</p> Halperin S Guiseppe F Scheifele D Gerard P Guiseppe S Cuccia M Willems P 25th International Congress of Paediatrics (ICP); 25–30 August; Athens, Greece 2007 <p>European Medicines Agency: ProQuad summary of product characteristics, 11 September 2008</p> http://www.emea.europa.eu/humandocs/PDFs/EPAR/proquad/062206en6.pdf <p>Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2007</p> Bernaola Iturbe E Gimenez Sanchez F Baca Cots M de Juan Martin F Diez Domingo J Garces Sanchez M Gomez-Campdera A Martinon-Torres F Picazo JJ Pineda Solas V An Pediatr (Barc) 2007 66 62 69 17266854 <p>Epidemiology of varicella in Connecticut, 2001–2005</p> Sosa LE Hadler JL J Infect Dis 2008 197 Suppl 2 S90 93 10.1086/522128 18419416 <p>Varicella vaccine effectiveness in the US vaccination program: a review</p> Seward J Marin M Vazquez M J Infect Dis 2008 197 S82 87 10.1086/522145 18419415 <p>Loss of vaccine-induced immunity to varicella over time</p> Chaves SS Gargiullo P Zhang JX Civen R Guris D Mascola L Seward JF N Engl J Med 2007 356 1121 1129 10.1056/NEJMoa064040 17360990 <p>Ten year follow-up of healthy children who received one or two injections of varicella vaccine</p> Kuter B Matthews H Shinefield H Black S Dennehy P Watson B Reisinger K Kim LL Lupinacci L Hartzel J Chan I Pediatr Infect Dis J 2004 23 132 137 10.1097/01.inf.0000109287.97518.67 14872179 <p>Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine</p> Nader S Bergen R Sharp M Arvin AM J Infect Dis 1995 171 13 17 7798653 <p>Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine</p> Watson B Boardman C Laufer D Piercy S Tustin N Olaleye D Cnaan A Starr SE Clin Infect Dis 1995 20 316 319 7742436 <p>MMR vaccination overview in European countries</p> http://www.euvac.net/graphics/euvac/vaccination/mmr.html <p>Measles vaccines</p> World Health Organization Wkly Epidemiol Rec 2004 79 130 142 15114951 <p>Antibody persistence and varicella breakthrough case assessment three years after administration of measles-mumps-rubella-varicella (MMRV) vaccine in children aged 11–23 months</p> Zepp F Manegold-Randel D Helm K Gildberg P Knuf M de la Bourdonnaye G Willems P 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID); 13–17 May; Graz, Austria 2008 <p>The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program</p> Peltola H Heinonen OP Valle M Paunio M Virtanen M Karanko V Cantell K N Engl J Med 1994 331 1397 1402 10.1056/NEJM199411243312101 7969278 <p>Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella (MMRV) vaccine in healthy children aged 5–6 years</p> Vesikari T Baer G Willems P Pediatr Infect Dis J 2007 26 153 158 10.1097/01.inf.0000250689.09396.21 17259879 <p>Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002</p> Jumaan AO Yu O Jackson LA Bohlke K Galil K Seward JF J Infect Dis 2005 191 2002 2007 10.1086/430325 15897984 <p>Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox</p> Brisson M Gay NJ Edmunds WJ Andrews NJ Vaccine 2002 20 2500 2507 10.1016/S0264-410X(02)00180-9 12057605 <p>Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study</p> Thomas SL Wheeler JG Hall AJ Lancet 2002 360 678 682 10.1016/S0140-6736(02)09837-9 12241874 <p>The incidence of herpes zoster in a United States administrative database</p> Insinga RP Itzler RF Pellissier JM Saddier P Nikas AA J Gen Intern Med 2005 20 748 753 1490195 16050886 10.1111/j.1525-1497.2005.0150.x <p>Risk of herpes zoster in adults immmunized with varicella vaccine</p> Hambleton S Steinberg SP LaRussa PS Shapiro ED Gershon AA J Infect Dis 2008 197 Suppl 2 S196 199 10.1086/522131 18419397 <p>The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group</p> Hardy I Gershon AA Steinberg SP LaRussa P N Engl J Med 1991 325 1545 1550 1658650 <p>A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons</p> Gershon AA Chen J Gershon MD J Infect Dis 2008 197 Suppl 2 S61 65 10.1086/522149 18419411 <p>Vaccination of children with perinatal HIV infection protects against varicella and zoster</p> Son M Shapiro E LaRussa P Neu N Michalik D Meglin M Bitar W Jurgrau A Flynn P Gershon A Pediatric Academic Societies' Annual Meeting; 2–6 May; Honolulu, Hawaii 2008 <p>Vaccination coverage for measles containing vaccines</p> http://data.euro.who.int/cisid/ <p>Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis</p> Hammerschmidt T Bisanz H Wutzler P Vaccine 2007 25 7307 7312 10.1016/j.vaccine.2007.08.017 17881097 <p>Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases</p> Bonanni P Boccalini S Bechini A Banz K Vaccine 2008 26 5619 5626 10.1016/j.vaccine.2008.07.096 18723062 <p>An economic analysis of the universal varicella vaccination program in the United States</p> Zhou F IR O-S Guris D Shefer A Lieu T Seward JF J Infect Dis 2008 197 Suppl 2 S156 164 10.1086/522135 18419391

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1741-7015/7/26/prepub